FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (46)Enhertu approved in EU for HER2+ solid tumours
Preheader (150)Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positi
Typography
Arial
Colors
Text Analysis
Body Words149
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px778 px
X-Spam Score1.6
Preheader OptimizedNo
Timing
Day of WeekMonday
TimeOvernight

Enhertu approved in EU for HER2+ solid tumours

Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positi
Enhertu approved in EU for HER2+ solid tumours